1. 他克莫司患者中有11.7%的患者出现ACR70反应,而米唑瑞滨患者则没有。
11.7% of the tacrolimus patients had an ACR70 response compared with none of the mizoribine patients.

来自互联网

2. 目的研究长春瑞滨联合外照射对人乳腺癌MCF - 7细胞的抗肿瘤机制。
Objective To investigate the mechanism of the anticancer action of vinorelbine combinated with radiation on human breast cancer cell line MCF-7.

来自互联网

3. 目的探讨长春瑞滨静脉注射外渗时采用不同药物局部封闭对损伤组织的保护作用。
Objective To research the protective effect of Lidocain in local blockade on tissue injury caused by extravasation of Vinorelbine.

来自互联网

4. 酒石酸长影响因素试验分别对样品进行了光、热、湿、酸、碱、氧化、还原降解。
The sample impress factor testing was performed under light heat humidity acidity alkaline oxidation reduction.

来自互联网

5. 目的观察以盖诺(国产长春瑞滨)为主的联合化疗方案治疗晚期恶性肿瘤的疗效及安全性。
Objective To evaluate the efficacy and toxicity of combined chemotherapy based on homemade vinorelbine in treating advanced malignant tumor.

来自互联网

6. 性别、年龄、身体质量指数(BMI)、化疗药物、长春瑞滨的剂量、化疗周期为临床相关因素。
Gender, age, body mass index (BMI), chemotherapeutic regimen, dose of Vinorelbine and chemotherapeutic cycle were used as clinical correlation factors.

来自互联网

7. 目的:观察奥沙利铂(OXA)联合长春瑞滨(VRB)治疗耐药非小细胞肺癌(NSCLC)的疗效与毒副反应。
Purpose: To observe the efficacy and the side effects of oxaliplatin (oxa) in combination with vinorelbine (VRB) in the treatment of drug resistant non-small-cell lung cancer (NSCLC).

来自互联网

8. 目的评价长春(NVB)与顺铂(DDP)及吉西他(GEM)与顺铂联合化疗治疗晚期非小细胞癌(NSCLC)的疗效及毒副作用。
Objective To evaluate the toxicity and clinical activity of navelbine(NVB) plus cisplation(DDP) and gemcitabine(GEM) plus cisplation in the treatment of advanced non-small cell lung cancer(NSCLC).

来自互联网

9. 目的评价长春(NVB)与顺铂(DDP)及吉西他(GEM)与顺铂联合化疗治疗晚期非小细胞癌(NSCLC)的疗效及毒副作用。
Objective To evaluate the toxicity and clinical activity of navelbine(NVB) plus cisplation(DDP) and gemcitabine(GEM) plus cisplation in the treatment of advanced non-small cell lung cancer(NSCLC).

来自互联网